The DOI matches its Crossref record; 770 of the 770 references it cites were found in a registry or an index.
Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures
Open accessAbstract
Virus-like particle (VLP) technology is a promising approach for the construction of novel vaccines, diagnostic tools, and gene therapy vectors. Initially, VLPs were primarily derived from non-enveloped icosahedral or helical viruses and proved to be viable vaccine candidates due to their effective presentation of epitopes in a native conformation. VLP technology has also been used to prepare chimeric VLPs decorated with genetically fused or chemically coupled epitope stretches selected from immunologically defined target proteins. However, structural constraints associated with the rigid geometrical architecture of icosahedral or helical VLPs pose challenges for the expression and presentation of large epitopes. Complex VLPs derived from non-symmetric enveloped viruses are increasingly being used to incorporate large epitopes and even full-length foreign proteins. Pleomorphic VLPs derived from influenza or other enveloped viruses can accommodate multiple full-length and/or chimeric proteins that can be rationally designed for multifunctional purposes, including multivalent vaccines. Therefore, a second generation of VLP carriers is represented by complex particles reconstructed from natural or chimeric structural proteins derived from complex enveloped viruses. Further development of safe and efficient VLP nanotechnology may require a rational combination of both approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Urisman, A., Molinaro, R. J., Fischer, N., Plummer, S. J., Casey, G., Klein, E. A., Malathi, K., Magi-Galluzzi, C., Tubbs, R. R., Ganem, D., et al. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020025 · Cited by 577
RetractedBradford, M. M. (1976) · Analytical Biochemistry · doi:10.1016/0003-2697(76)90527-3 · Cited by 255,302
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
DNA sequencing with chain-terminating inhibitors
Sanger, F., Nicklen, S., & Coulson, A. R. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.12.5463 · Cited by 68,572
Thompson, J. D., Higgins, D. G., & Gibson, T. J. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.22.4673 · Cited by 64,617
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
A simple method for displaying the hydropathic character of a protein
Kyte, J., & Doolittle, R. F. (1982) · Journal of Molecular Biology · doi:10.1016/0022-2836(82)90515-0 · Cited by 22,843
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells.
Gorman, C. M., Moffat, L. F., & Howard, B. H. (1982) · Molecular and Cellular Biology · doi:10.1128/mcb.2.9.1044 · Cited by 7,830
[6] Use of T7 RNA polymerase to direct expression of cloned genes
William Studier, F., Rosenberg, A. H., Dunn, J. J., & Dubendorff, J. W. (1990) · Methods in Enzymology · doi:10.1016/0076-6879(90)85008-c · Cited by 6,562
Cited by
Items 101–200 of 321
Zhao, Z., Fu, J., Dhakal, S., Johnson-Buck, A., Liu, M., Zhang, T., Woodbury, N. W., Liu, Y., Walter, N. G., & Yan, H. (2016) · Nature Communications · doi:10.1038/ncomms10619 · Cited by 430
Prophylactic human papillomavirus vaccines
Lowy, D. R. (2006) · Journal of Clinical Investigation · doi:10.1172/jci28607 · Cited by 428
Tbe complete nudeotide sequences of the cloned hepatitis B vims DNA; subtype adr and adw
Ono, Y., Onda, H., Sasada, R., Igarashi, K., Sugino, Y., & Nishioka, K. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.6.1747 · Cited by 427
T-cell epitope vaccine design by immunoinformatics
Patronov, A., & Doytchinova, I. (2013) · Open Biology · doi:10.1098/rsob.120139 · Cited by 426
Segel, M., Lash, B., Song, J., Ladha, A., Liu, C. C., Jin, X., Mekhedov, S. L., Macrae, R. K., Koonin, E. V., & Zhang, F. (2021) · Science · doi:10.1126/science.abg6155 · Cited by 423
Lee, L. Y.-H., Ha, D. L. A., Simmons, C., de Jong, M. D., Chau, N. V. V., Schumacher, R., Peng, Y. C., McMichael, A. J., Farrar, J. J., Smith, G. L., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32460 · Cited by 422
Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine
Neafsey, D. E., Juraska, M., Bedford, T., Benkeser, D., Valim, C., Griggs, A., Lievens, M., Abdulla, S., Adjei, S., Agbenyega, T., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505819 · Cited by 422
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41–gp120 interface
Huang, J., Kang, B. H., Pancera, M., Lee, J. H., Tong, T., Feng, Y., Imamichi, H., Georgiev, I. S., Chuang, G.-Y., Druz, A., et al. (2014) · Nature · doi:10.1038/nature13601 · Cited by 420
Orchestrating house dust mite-associated allergy in the lung
Gregory, L. G., & Lloyd, C. M. (2011) · Trends in Immunology · doi:10.1016/j.it.2011.06.006 · Cited by 420
Herrewegh, A. A. P. M., Smeenk, I., Horzinek, M. C., Rottier, P. J. M., & de Groot, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4508-4514.1998 · Cited by 419
Aptamers Chemistry: Chemical Modifications and Conjugation Strategies
Odeh, F., Nsairat, H., Alshaer, W., Ismail, M. A., Esawi, E., Qaqish, B., Bawab, A. A., & Ismail, S. I. (2019) · Molecules · doi:10.3390/molecules25010003 · Cited by 415
Virus trafficking – learning from single-virus tracking
Brandenburg, B., & Zhuang, X. (2007) · Nature Reviews Microbiology · doi:10.1038/nrmicro1615 · Cited by 413
Allergen immunotherapy: past, present and future
Durham, S. R., & Shamji, M. H. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00786-1 · Cited by 413
Plug-and-Display: decoration of Virus-Like Particles via isopeptide bonds for modular immunization
Brune, K. D., Leneghan, D. B., Brian, I. J., Ishizuka, A. S., Bachmann, M. F., Draper, S. J., Biswas, S., & Howarth, M. (2016) · Scientific Reports · doi:10.1038/srep19234 · Cited by 412
Rabbit haemorrhagic disease (RHD) and rabbit haemorrhagic disease virus (RHDV): a review
Abrantes, J., van der Loo, W., Le Pendu, J., & Esteves, P. J. (2012) · Veterinary Research · doi:10.1186/1297-9716-43-12 · Cited by 411
Interferons and viruses: an evolutionary arms race of molecular interactions
Hoffmann, H.-H., Schneider, W. M., & Rice, C. M. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.01.004 · Cited by 410
Nanotechnology for protein delivery: Overview and perspectives
Yu, M., Wu, J., Shi, J., & Farokhzad, O. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.012 · Cited by 410
Turcot, V., Lu, Y., Highland, H. M., Schurmann, C., Justice, A. E., Fine, R. S., Bradfield, J. P., Esko, T., Giri, A., Graff, M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-017-0011-x · Cited by 409
Lerner, R. A., Green, N., Alexander, H., Liu, F. T., Sutcliffe, J. G., & Shinnick, T. M. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.6.3403 · Cited by 409
Qiu, J., Söderlund-Venermo, M., & Young, N. S. (2017) · Clinical Microbiology Reviews · doi:10.1128/cmr.00040-16 · Cited by 407
Brief update on endocytosis of nanomedicines
Patel, S., Kim, J., Herrera, M., Mukherjee, A., Kabanov, A. V., & Sahay, G. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.08.004 · Cited by 400
Daniell, H., Lee, S.-B., Panchal, T., & Wiebe, P. O. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4921 · Cited by 398
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
Liu, W. J., Zhao, M., Liu, K., Xu, K., Wong, G., Tan, W., & Gao, G. F. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.006 · Cited by 395
Molecular farming of pharmaceutical proteins
Fischer, R., & Emans, N. (2000) · Transgenic Research · doi:10.1023/a:1008975123362 · Cited by 394
Viral Nanoparticles for Drug Delivery, Imaging, Immunotherapy, and Theranostic Applications
Chung, Y. H., Cai, H., & Steinmetz, N. F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.024 · Cited by 391
Vaccination Strategies for Mucosal Immune Responses
Ogra, P. L., Faden, H., & Welliver, R. C. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.2.430-445.2001 · Cited by 390
Hepatitis C Virus Glycoproteins Interact with DC-SIGN and DC-SIGNR
Pöhlmann, S., Zhang, J., Baribaud, F., Chen, Z., Leslie, G. J., Lin, G., Granelli-Piperno, A., Doms, R. W., Rice, C. M., & McKeating, J. A. (2003) · Journal of Virology · doi:10.1128/jvi.77.7.4070-4080.2003 · Cited by 389
Bacterial flagellin—a potent immunomodulatory agent
Hajam, I. A., Dar, P. A., Shahnawaz, I., Jaume, J. C., & Lee, J. H. (2017) · Experimental & Molecular Medicine · doi:10.1038/emm.2017.172 · Cited by 387
Recent Advances of Vaccine Adjuvants for Infectious Diseases
Lee, S., & Nguyen, M. T. (2015) · Immune Network · doi:10.4110/in.2015.15.2.51 · Cited by 385
Antimicrobial Peptides as Anticancer Agents: Functional Properties and Biological Activities
Tornesello, A. L., Borrelli, A., Buonaguro, L., Buonaguro, F. M., & Tornesello, M. L. (2020) · Molecules · doi:10.3390/molecules25122850 · Cited by 383
Rose, R. C., Bonnez, W., Reichman, R. C., & Garcea, R. L. (1993) · Journal of Virology · doi:10.1128/jvi.67.4.1936-1944.1993 · Cited by 381
Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma
Llovet, J. M., Pinyol, R., Yarchoan, M., Singal, A. G., Marron, T. U., Schwartz, M., Pikarsky, E., Kudo, M., & Finn, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00868-0 · Cited by 391
Assembly and budding of influenza virus
Nayak, D. P., Hui, E. K.-W., & Barman, S. (2004) · Virus Research · doi:10.1016/j.virusres.2004.08.012 · Cited by 379
Design of virus-based nanomaterials for medicine, biotechnology, and energy
Wen, A. M., & Steinmetz, N. F. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00287g · Cited by 379
Perlmutter, J. D., & Hagan, M. F. (2015) · Annual Review of Physical Chemistry · doi:10.1146/annurev-physchem-040214-121637 · Cited by 376
Recent progress in targeted delivery vectors based on biomimetic nanoparticles
Chen, L., Hong, W., Ren, W., Xu, T., Qian, Z., & He, Z. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00631-2 · Cited by 374
The structural biology of PRRSV
Dokland, T. (2010) · Virus Research · doi:10.1016/j.virusres.2010.07.029 · Cited by 366
Yu, F., Du, L., Ojcius, D. M., Pan, C., & Jiang, S. (2020) · Microbes and Infection · doi:10.1016/j.micinf.2020.01.003 · Cited by 366
Penna, A., Chisari, F. V., Bertoletti, A., Missale, G., Fowler, P., Giuberti, T., Fiaccadori, F., & Ferrari, C. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.6.1565 · Cited by 365
Persistent and Transient Replication of Full-Length Hepatitis C Virus Genomes in Cell Culture
Pietschmann, T., Lohmann, V., Kaul, A., Krieger, N., Rinck, G., Rutter, G., Strand, D., & Bartenschlager, R. (2002) · Journal of Virology · doi:10.1128/jvi.76.8.4008-4021.2002 · Cited by 364
Abd El-Aziz, T. M., & Stockand, J. D. (2020) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2020.104327 · Cited by 363
Nanovehicular Intracellular Delivery Systems
Prokop, A., & Davidson, J. M. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21270 · Cited by 363
Emerging biomedical applications of synthetic biology
Weber, W., & Fussenegger, M. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3094 · Cited by 362
Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens
Akdis, C. A., & Akdis, M. (2015) · World Allergy Organization Journal · doi:10.1186/s40413-015-0063-2 · Cited by 361
CD81 Is Required for Hepatitis C Virus Glycoprotein-Mediated Viral Infection
Zhang, J., Randall, G., Higginbottom, A., Monk, P., Rice, C. M., & McKeating, J. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.3.1448-1455.2004 · Cited by 361
Bioengineering virus‐like particles as vaccines
Lua, L. H. L., Connors, N. K., Sainsbury, F., Chuan, Y. P., Wibowo, N., & Middelberg, A. P. J. (2014) · Biotechnology and Bioengineering · doi:10.1002/bit.25159 · Cited by 355
Self-assembling protein nanoparticles in the design of vaccines
López-Sagaseta, J., Malito, E., Rappuoli, R., & Bottomley, M. J. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2015.11.001 · Cited by 353
Dissecting Polyclonal Vaccine-Induced Humoral Immunity against HIV Using Systems Serology
Chung, A. W., Kumar, M. P., Arnold, K. B., Yu, W. H., Schoen, M. K., Dunphy, L. J., Suscovich, T. J., Frahm, N., Linde, C., Mahan, A. E., et al. (2015) · Cell · doi:10.1016/j.cell.2015.10.027 · Cited by 352
Ebola Virus VP40 Drives the Formation of Virus-Like Filamentous Particles Along with GP
Noda, T., Sagara, H., Suzuki, E., Takada, A., Kida, H., & Kawaoka, Y. (2002) · Journal of Virology · doi:10.1128/jvi.76.10.4855-4865.2002 · Cited by 349
Bartenschlager, R., & Schaller, H. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05420.x · Cited by 347
Mangeot, P. E., Risson, V., Fusil, F., Marnef, A., Laurent, E., Blin, J., Mournetas, V., Massouridès, E., Sohier, T. J. M., Corbin, A., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07845-z · Cited by 346
Surveillance of Vaccination Coverage Among Adult Populations —United States, 2018
Lu, P.-J., Hung, M.-C., Srivastav, A., Grohskopf, L. A., Kobayashi, M., Harris, A. M., Dooling, K. L., Markowitz, L. E., Rodriguez-Lainz, A., & Williams, W. W. (2021) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss7003a1 · Cited by 346
Do Kwon, Y., Pancera, M., Acharya, P., Georgiev, I. S., Crooks, E. T., Gorman, J., Joyce, M. G., Guttman, M., Ma, X., Narpala, S., et al. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3051 · Cited by 345
Dispinseri, S., Secchi, M., Pirillo, M. F., Tolazzi, M., Borghi, M., Brigatti, C., De Angelis, M. L., Baratella, M., Bazzigaluppi, E., Venturi, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22958-8 · Cited by 344
Insect cells as hosts for the expression of recombinant glycoproteins
Altmann, F., Staudacher, E., Wilson, I. B. H., & März, L. (1999) · Glycoconjugate Journal · doi:10.1023/a:1026488408951 · Cited by 344
Japanese Encephalitis—A Pathological and Clinical Perspective
Ghosh, D., & Basu, A. (2009) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000437 · Cited by 340
Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery
Rohovie, M. J., Nagasawa, M., & Swartz, J. R. (2017) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10049 · Cited by 340
Barreira da Silva, R., Laird, M. E., Yatim, N., Fiette, L., Ingersoll, M. A., & Albert, M. L. (2015) · Nature Immunology · doi:10.1038/ni.3201 · Cited by 337
Vaccines, new opportunities for a new society
Rappuoli, R., Pizza, M., Del Giudice, G., & De Gregorio, E. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1402981111 · Cited by 335
Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination
Nochi, T., Takagi, H., Yuki, Y., Yang, L., Masumura, T., Mejima, M., Nakanishi, U., Matsumura, A., Uozumi, A., Hiroi, T., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703766104 · Cited by 335
Freed, E. O., & Martin, M. A. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.341-351.1996 · Cited by 335
Plant‐made vaccines for humans and animals
Rybicki, E. P. (2010) · Plant Biotechnology Journal · doi:10.1111/j.1467-7652.2010.00507.x · Cited by 334
Bacteriophage lambda: Early pioneer and still relevant
Casjens, S. R., & Hendrix, R. W. (2015) · Virology · doi:10.1016/j.virol.2015.02.010 · Cited by 334
Opportunities and challenges for human papillomavirus vaccination in cancer
Roden, R. B. S., & Stern, P. L. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2018.13 · Cited by 333
Next-generation influenza vaccines: opportunities and challenges
Wei, C.-J., Crank, M. C., Shiver, J., Graham, B. S., Mascola, J. R., & Nabel, G. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0056-x · Cited by 332
Adriaenssens, A. E., Biggs, E. K., Darwish, T., Tadross, J., Sukthankar, T., Girish, M., Polex-Wolf, J., Lam, B. Y., Zvetkova, I., Pan, W., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.07.013 · Cited by 324
Biomimetic Nanotechnology toward Personalized Vaccines
Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2020) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 328
Modified Vaccinia Virus Ankara
Volz, A., & Sutter, G. (2017) · Advances in Virus Research · doi:10.1016/bs.aivir.2016.07.001 · Cited by 323
Emerging Concepts and Technologies in Vaccine Development
Brisse, M., Vrba, S. M., Kirk, N., Liang, Y., & Ly, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583077 · Cited by 323
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
Cellular Networks Involved in the Influenza Virus Life Cycle
Watanabe, T., Watanabe, S., & Kawaoka, Y. (2010) · Cell Host & Microbe · doi:10.1016/j.chom.2010.05.008 · Cited by 321
Ma, J. K. ‐., Barros, E., Bock, R., Christou, P., Dale, P. J., Dix, P. J., Fischer, R., Irwin, J., Mahoney, R., Pezzotti, M., et al. (2005) · EMBO reports · doi:10.1038/sj.embor.7400470 · Cited by 321
Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach
Talon, J., Salvatore, M., O'Neill, R. E., Nakaya, Y., Zheng, H., Muster, T., García-Sastre, A., & Palese, P. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.070525997 · Cited by 320
Vaccine protection by a triple deletion mutant of simian immunodeficiency virus
Wyand, M. S., Manson, K. H., Garcia-Moll, M., Montefiori, D., & Desrosiers, R. C. (1996) · Journal of Virology · doi:10.1128/jvi.70.6.3724-3733.1996 · Cited by 320
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Wu, J., & Waxman, D. J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.01.050 · Cited by 320
Production of virus-like particles for vaccines
Fuenmayor, J., Gòdia, F., & Cervera, L. (2017) · New Biotechnology · doi:10.1016/j.nbt.2017.07.010 · Cited by 318
Quan, F.-S., Huang, C., Compans, R. W., & Kang, S.-M. (2007) · Journal of Virology · doi:10.1128/jvi.02052-06 · Cited by 313
Betanodavirus and VER Disease: A 30-year Research Review
Bandín, I., & Souto, S. (2020) · Pathogens · doi:10.3390/pathogens9020106 · Cited by 310
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y.-X. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 308
Promises and Pitfalls of Intracellular Delivery of Proteins
Fu, A., Tang, R., Hardie, J., Farkas, M. E., & Rotello, V. M. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500320j · Cited by 306
Chen, B. J., Leser, G. P., Morita, E., & Lamb, R. A. (2007) · Journal of Virology · doi:10.1128/jvi.00361-07 · Cited by 305
Bertoletti, A., Ferrari, C., Fiaccadori, F., Penna, A., Margolskee, R., Schlicht, H. J., Fowler, P., Guilhot, S., & Chisari, F. V. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10445 · Cited by 301
Nanoparticle-Based Vaccines Against Respiratory Viruses
Al-Halifa, S., Gauthier, L., Arpin, D., Bourgault, S., & Archambault, D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00022 · Cited by 299
Baumann, V., & Winkler, J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.116 · Cited by 297
Matrix Protein 2 Vaccination and Protection against Influenza Viruses, Including Subtype H5N1
Tompkins, S. M., Zhao, Z.-S., Lo, C.-Y., Misplon, J. A., Liu, T., Ye, Z., Hogan, R. J., Wu, Z., Benton, K. A., Tumpey, T. M., et al. (2007) · Emerging Infectious Diseases · doi:10.3201/eid1303.061125 · Cited by 297
Bartholomeeusen, K., Daniel, M., LaBeaud, D. A., Gasque, P., Peeling, R. W., Stephenson, K. E., Ng, L. F. P., & Ariën, K. K. (2023) · Nature Reviews Disease Primers · doi:10.1038/s41572-023-00429-2 · Cited by 297
Genomic structure of tbe large RNA segment of infectious bursal disease virus
Hudson, P. J., McKern, N. M., Power, B. E., & Azad, A. A. (1986) · Nucleic Acids Research · doi:10.1093/nar/14.12.5001 · Cited by 296
Long-lasting memory T cell responses following self-limited acute hepatitis B.
Penna, A., Artini, M., Cavalli, A., Levrero, M., Bertoletti, A., Pilli, M., Chisari, F. V., Rehermann, B., Del Prete, G., Fiaccadori, F., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118902 · Cited by 296
Vaccine adjuvants: Current challenges and future approaches
Wilson-Welder, J. H., Torres, M. P., Kipper, M. J., Mallapragada, S. K., Wannemuehler, M. J., & Narasimhan, B. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21523 · Cited by 296
Cytotoxic T lymphocyte responsiveness after resolution of chronic hepatitis B virus infection.
Rehermann, B., Lau, D., Hoofnagle, J. H., & Chisari, F. V. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118592 · Cited by 294
Systematic Surface Engineering of Magnetic Nanoworms for In vivo Tumor Targeting
Park, J., von Maltzahn, G., Zhang, L., Derfus, A. M., Simberg, D., Harris, T. J., Ruoslahti, E., Bhatia, S. N., & Sailor, M. J. (2009) · Small · doi:10.1002/smll.200801789 · Cited by 293
Collins, E. J., Bowyer, C., Tsouza, A., & Chopra, M. (2022) · Biology · doi:10.3390/biology11020239 · Cited by 293
Understanding and learning from the success of prophylactic human papillomavirus vaccines
Schiller, J. T., & Lowy, D. R. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2872 · Cited by 293
A colorimetric method for DNA hybridization
Renz, M., & Kurz, C. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.8.3435 · Cited by 292
Immunogenicity in humans of an edible vaccine for hepatitis B
Thanavala, Y., Mahoney, M., Pal, S., Scott, A., Richter, L., Natarajan, N., Goodwin, P., Arntzen, C. J., & Mason, H. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409899102 · Cited by 290
Atomic model of the papillomavirus capsid
Modis, Y. (2002) · The EMBO Journal · doi:10.1093/emboj/cdf494 · Cited by 290
Maturation of Papillomavirus Capsids
Buck, C. B., Thompson, C. D., Pang, Y.-Y. S., Lowy, D. R., & Schiller, J. T. (2005) · Journal of Virology · doi:10.1128/jvi.79.5.2839-2846.2005 · Cited by 289
Hepatitis B virus morphogenesis
Bruss, V. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i1.65 · Cited by 289
Freed, E. O., Orenstein, J. M., Buckler-White, A. J., & Martin, M. A. (1994) · Journal of Virology · doi:10.1128/jvi.68.8.5311-5320.1994 · Cited by 289
Virus-like particle vaccinology, from bench to bedside
Mohsen, M. O., & Bachmann, M. F. (2022) · Cellular & Molecular Immunology · doi:10.1038/s41423-022-00897-8 · Cited by 289
Metadata
- Authors
- Pushko, P., Pumpens, P., & Grens, E.
- Venue
- Intervirology
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 56
- Issue
- 3
- Pages
- 141-165
- ISSN
- 0300-5526 (ISSN-L)
- 1423-0100
- OpenAlex
- W2046182783
- Cited by
- 5,950
- References
- 770
- FWCI
- 295.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.